Steven Wilson
Psychiatric/Mental Health, Child & Adolescent · Anderson, INNPI 1104137124
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 427 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 26.7% of the total. Reporting peaked in 2023 at $1,882 and has fallen 75.5% since, to $462 in 2025.
Across 427 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Ironshore Pharmaceuticals Inc.$704
- Alkermes, Inc.$701
- Supernus Pharmaceuticals, Inc.$533
- Takeda Pharmaceuticals U.S.A., Inc.$456
- Corium, LLC$377
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,14399%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,651 |
| Ironshore Pharmaceuticals Inc. | 43 | $704 |
| Alkermes, Inc. | 32 | $701 |
| Supernus Pharmaceuticals, Inc. | 117 | $533 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $456 |
| Corium, LLC | 23 | $377 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $375 |
| Vanda Pharmaceuticals Inc. | 11 | $248 |
| Bausch Health US, LLC | 21 | $175 |
| Neos Therapeutics, LP | 10 | $170 |
| Adlon Therapeutics L.p. | 8 | $161 |
| Sunovion Pharmaceuticals Inc. | 8 | $112 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Lundbeck LLC | 5 | $72 |
| Collegium Pharmaceutical, Inc. | 4 | $72 |
| Axsome Therapeutics, Inc. | 4 | $66 |
| Jazz Pharmaceuticals Inc. | 2 | $42 |
| Johnson & Johnson | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Eisai Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
| Tris Pharma Inc | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few psychiatric/mental health, child & adolescent providers in Indianato place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 21 | $5,490 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $1,971 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $527 |
| Clonazepam | 19 | $260 |
| Buspirone Hcl | 14 | $127 |
| Sertraline Hcl | 11 | $90 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health, child & adolescent in Anderson
- Pamela StachlerDanville$12K
- Susan KerseyLafayette$2K
- Bonnie FryeShelbyville$2K
- Joyce BriggsGreenwood$464
- Brenda Costello WellsIndianapolis$422
- Laura HawkinsLafayette$357
- Yolanda BrayColumbus$330
- Mary BalleBloomington$131
- Charlotte HannahRichmond$87
- Ukamaka OrucheIndianapolis$47
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.